Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy

Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy

Virotherapy on the basis of oncolytic vaccinia virus (VACV) strains is a novel approach for canine cancer therapy. Here we describe, for the first time, the characterization and the use of VACV strain GLV-5b451 expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb...

Full description

Bibliographic Details
Main Authors: Marion Adelfinger, Simon Bessler, Alexa Frentzen, Alexander Cecil, Johanna Langbein-Laugwitz, Ivaylo Gentschev, Aladar A. Szalay
Format: Article
Language:English
Published: MDPI AG 2015-07-01
Series:Viruses
Subjects:
oncolytic virus
cancer
canine cancer cell lines
antibody production
angiogenesis
canine soft tissue sarcoma (CSTS)
canine cancer therapy
Online Access:http://www.mdpi.com/1999-4915/7/7/2811

Internet

http://www.mdpi.com/1999-4915/7/7/2811

Similar Items